Multiple Sclerosis

The AJMC® Multiple Sclerosis compendium is a comprehensive resource for clinical news and expert insights for the disabling disease that impacts the brain and spinal cord.

Latest News

BMI - Olivier Le Moal
Study Finds Obesity May Worsen Multiple Sclerosis: Genetic Analysis Points to Causal Link

November 21st 2024

A new study aimed at exploring the relationship between obesity and multiple sclerosis severity using genetic data finds that higher BMI and other obesity measures were associated with increased disability progression in patients with MS.

Doctor examining MRI images of multiple sclerosis MS | Image Credit: © New Africa - stock.adobe.com
Lesion Repair, Damage Processes Correlate With MS Disease Characteristics

November 11th 2024

Neurologic disease concept | image credit: ralwel - stock.adobe.com
Fexagratinib in MS Shows Promise for Human Use

November 9th 2024

MS word cloud | Image Credit: © arloo-stock.adobe.com
Exploring Metabolic Links to Cognitive Impairment in MS

November 8th 2024

Fingolimod | Image Credit: © María Pilar Martínez - stock.adobe.com
Fingolimod-Induced Heart Rate Slowing Tied to Parasympathetic Dominance in MS

October 26th 2024

Examining the Role of a Novel Class of Medications for the Management of Multiple Sclerosis

This video series provides an in-depth look at multiple sclerosis, covering its impact, pathophysiology, treatment strategies, unmet needs, patient satisfaction, and future research. Gain key insights into managing and understanding this condition.

This video series provides an in-depth look at multiple sclerosis, covering its impact, pathophysiology, treatment strategies, unmet needs, patient satisfaction, and future research. Gain valuable insights into managing and understanding this complex condition.
Continuing Medical Education
View All
November 21st 2024

Assessing the Treatment Landscape for Multiple Sclerosis to Better Individualize Care

1.5 Credits / Neurology
November 21st 2024

Exploring Transthyretin-Mediated Amyloidosis and Its Phenotypes: A Comprehensive Approach to Patient Treatment

1.5 Credits / Cardiology, Neurology, Rare Diseases
November 21st 2024

The Role of the Specialty Pharmacist in Optimizing Treatment for Amyotrophic Lateral Sclerosis: The Impact of Early Intervention, Patient-Centered Care, and Disease-Modifying Therapies in Slowing Disease Progression

1.0 Credit / Neurology
November 21st 2024

Advancing Targeted Therapies Aimed at Smoldering Disease in Multiple Sclerosis

1.0 Credit / Immunology, Neurology
November 21st 2024

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology

More News

Strengthening the Assessment of Long-Term Treatment Outcomes in MS
October 4th 2013

Strengthening the Assessment of Long-Term Treatment Outcomes in MS

The gold standard for measuring treatment outcomes in multiple sclerosis (MS) is the randomized clinical trial (RCT). However, RCTs are often short-sighted and biased in their execution. Dr Maria Sormani, PhD, Biostatistics Unit, Department of Health Sciences, University of Genoa, Genoa, Italy, addressed this problem in a lecture on immunomodulatory treatment of MS.
Fred Lublin, MD, Examines Research and Key Takeaways from ECTRIMS 2013
October 4th 2013

Fred Lublin, MD, Examines Research and Key Takeaways from ECTRIMS 2013

In this video, Fred Lublin, MD, Saunders Family professor of neurology, director, The Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Icahn School of Medicine at Mount Sinai, discussed the results of his poster presentation, Natalizumab Reduces the Disabling Amplitude of Multiple Sclerosis Relapses and Improves Post-relapse Residual Disability.
A Look at the Widespread Economic Burden of Multiple Sclerosis
October 4th 2013

A Look at the Widespread Economic Burden of Multiple Sclerosis

Clinical trials and treatment in multiple sclerosis (MS) place an unwelcome economic burden upon countries with MS prevalence. With rising costs and a growing interest in MS clinical trials from emerging countries, new studies are needed to evaluate the significance of these factors.
Fatigue and Cognitive Impairment in Multiple Sclerosis
October 4th 2013

Fatigue and Cognitive Impairment in Multiple Sclerosis

Fatigue and cognitive impairment are 2 of the most common health problems associated with multiple sclerosis (MS). Recent MS studies evaluate the nature of these 2 conditions not just as side effects of MS, but as chronic conditions with varying degrees of severity based on objective assessment and self-perception.
Barry Singer, MD, Answers how the ACA will affect MS Patients
October 4th 2013

Barry Singer, MD, Answers how the ACA will affect MS Patients

Barry Singer, MD, director, MS Center for Innovations in Care, St. Louis, MO, said that the Affordable Care Act could cause challenges in terms of coverage.
Tecfidera and Ampyra Show Potential for Quality-of-Life Improvement in Patients With MS
October 4th 2013

Tecfidera and Ampyra Show Potential for Quality-of-Life Improvement in Patients With MS

New disease-modifying drugs in multiple sclerosis (MS) show potential for improving quality-of-life (QoL) of patients with multiple sclerosis. The clinical benefits of dimethyl fumarate and PR-fampridine were discussed at a Biogen Idec-sponsored satellite symposium at the 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS).
Daniel Kantor, MD, Addresses Risk Management in New Multiple Sclerosis Agents
October 3rd 2013

Daniel Kantor, MD, Addresses Risk Management in New Multiple Sclerosis Agents

Daniel Kantor, MD, medical director, Neurologique, immediate past president, Florida Society of Neurology, said that after an initial diagnosis of multiple sclerosis (MS) is made, providers must compare risks versus benefits when choosing which agent to treat with.
The Place of Genetics in MS Research
October 3rd 2013

The Place of Genetics in MS Research

Recent discussions of risk gene variation and pharmacogenitc studies were highlighted at a parallel session during the 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). Genome-Wide Association Studies (GWAS) have identified over 100 common risk variants in just over a quarter of observed heritability.
The Probability of Early Prediction in MS Disease Activity
October 3rd 2013

The Probability of Early Prediction in MS Disease Activity

Predictors of long-term disability and treatment failure in multiple sclerosis were discussed at a platform presentation during the 29th Congress European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). In the first presentation discussed here, Marzia Romeo, MD, San Raffaele Hospital, Milan, Italy, shared findings from an observational study examining the viability of early prediction of long-term treatment failure in relapsing remitting multiple sclerosis (RRMS) patients treated with disease-modifying treatments (DMT).
Recent studies in the uses of Natalizumab and Peginterferon Beta-1a to Treat Relapsing-Remitting Multiple Sclerosis
October 3rd 2013

Recent studies in the uses of Natalizumab and Peginterferon Beta-1a to Treat Relapsing-Remitting Multiple Sclerosis

At a satellite symposium during the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) conference, presenters focused upon the usage of disease-modifying treatments (DMT) in relapsing-remitting multiple sclerosis (RRMS).
Self-Reporting in MS: Bridging the Knowledge Gap Between Patients and Physicians
October 3rd 2013

Self-Reporting in MS: Bridging the Knowledge Gap Between Patients and Physicians

Self-reporting among multiple sclerosis (MS) patients was the focus of 2 posters during a Quality of Life (QoL) poster session at the 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS).
Daniel Kantor, MD, on Specialty Pharmacy in Multiple Sclerosis
October 2nd 2013

Daniel Kantor, MD, on Specialty Pharmacy in Multiple Sclerosis

In the last two decades we've seen really an explosion of the treatments we have for multiple sclerosis (MS), said Daniel Kantor, MD, medical director, Neurologique, immediate past president, Florida Society of Neurology.
Brenda Banwell, MD, Discusses Treatment Options for Pediatric Multiple Sclerosis
October 2nd 2013

Brenda Banwell, MD, Discusses Treatment Options for Pediatric Multiple Sclerosis

Brenda Banwell, MD, Chief, Division of Neurology, Professor of Neurology, Perelman School of Medicine at the University of Pennsylvania, said that there are 3 areas of treatment associated with pediatric multiple sclerosis (MS).
Patricia Coyle, MD, Discusses Diagnostic Tools Utilized in Multiple Sclerosis
October 2nd 2013

Patricia Coyle, MD, Discusses Diagnostic Tools Utilized in Multiple Sclerosis

In this video, Patricia Coyle, MD, director, MS Comprehensive Care Center, Stony Brook Neurosciences Institute, professor and vice chair of clinical affairs, Department of Neurology, SUNY at Stony Brook, emphasized the need to establish biomarkers for the treatment of multiple sclerosis.
Episode 15 - SLE: Expectations As the Drug Market Evolves
July 23rd 2013

Episode 15 - SLE: Expectations As the Drug Market Evolves

Episode 19 - The Future of SLE and Hemophilia
July 23rd 2013

Episode 19 - The Future of SLE and Hemophilia

Episode 18 - The Role of Specialty Pharmacies in Rare Diseases
July 23rd 2013

Episode 18 - The Role of Specialty Pharmacies in Rare Diseases

Episode 17 - Future Outlook on the Orphan Drug Market
July 23rd 2013

Episode 17 - Future Outlook on the Orphan Drug Market

Episode 16 - Factors Hindering Care for SLE Patients
July 23rd 2013

Episode 16 - Factors Hindering Care for SLE Patients

Episode 13 - Challenges of Measuring the Outcomes of SLE
July 23rd 2013

Episode 13 - Challenges of Measuring the Outcomes of SLE

Episode 14 - Unmet Needs for Treatment of SLE
July 23rd 2013

Episode 14 - Unmet Needs for Treatment of SLE

Episode 12 - Recognizing the Strengths and Weaknesses of Current Clinical Practice Guidelines
July 23rd 2013

Episode 12 - Recognizing the Strengths and Weaknesses of Current Clinical Practice Guidelines

Episode 11 - Minimizing the Burden of SLE
July 23rd 2013

Episode 11 - Minimizing the Burden of SLE

Episode 10 - Treating Mild and Severe Hemophilia
July 23rd 2013

Episode 10 - Treating Mild and Severe Hemophilia

Episode 9 - The Future Landscape for the Treatment of Hemophilia
July 23rd 2013

Episode 9 - The Future Landscape for the Treatment of Hemophilia

Episode 8 - Long-Acting Agents and Considerations
July 23rd 2013

Episode 8 - Long-Acting Agents and Considerations

Episode 7 - Minimizing the Burden of SLE
July 23rd 2013

Episode 7 - Minimizing the Burden of SLE

Episode 6 - Addressing the Gaps in Care for Hemophilia Patients
July 23rd 2013

Episode 6 - Addressing the Gaps in Care for Hemophilia Patients

Episode 5 - Current Therapeutic Strategies for Hemophilia
July 23rd 2013

Episode 5 - Current Therapeutic Strategies for Hemophilia

Episode 4 - A Clinical Overview of Hemophilia
July 23rd 2013

Episode 4 - A Clinical Overview of Hemophilia

<1
...
1415161718192021>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo